UICC study group on basic and clinical cancer research: interrelations of signaling paths and what we can learn from interfering with them.
Burger
Max M
MM
Novartis Science Board, Novartis Intl. AG, CH-4002 Basel, Switzerland. max.burger@group.novartis.com
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002453:Cell Cycle; D002875:Chromosomes; D004261:DNA Replication; D005786:Gene Expression Regulation; D016147:Genes, Tumor Suppressor; D006801:Humans; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000209:etiology* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D016283:Proto-Oncogene Proteins p21(ras) / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000502:physiology
D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)